The haplo-HSCT platform offered to the cohort of pediatric patients analyzed in this study took advantage of an innovative strategy based on the selective depletion of αβT lymphocytes (major responsible of GvHD) and CD19+ B cells (responsible of post-transplant EBV-related lymphoproliferative disorders) [46]. Here, CD19 is linked to graft versus host disease.